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ABSTRACT
Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the
appropriate role and timing of transplantation are unclear. In this analysis, we report the outcomes of 46
patients with advanced CLL who underwent nonmyeloablative stem cell transplantation (NST) from HLA-
matched unrelated (67%) or related (33%) donors. Fludarabine (30 mg/m2  4) and low-dose intravenous
busulfan (0.8 mg/kg/day 4) were used for conditioning. The 2-year overall survival (OS) and progression-free
survival (PFS) rates in this refractory patient population were 54% and 34%, respectively, with a median
follow-up of 20 months. The primary cause of treatment failure was relapse, with a 2-year cumulative incidence
of 48%. High hematopoietic donor chimerism> 75% at day30 was a significant predictor of 2-year PFS (47%
vs 11%; P  .03). In multivariate analysis, chemotherapy-refractory disease at transplantation was associated
with a 3.2-fold risk of progression (P  .01) and a 4.6-fold risk of death (P  .02). Increasing number of
previous therapies and increasing bone marrow involvement were also associated with decreased PFS and OS.
These results suggest that NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment
option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to
achieve long-term disease control in a high proportion of patients.
© 2006 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Despite recent therapeutic advances that include
onoclonal antibody therapy with alemtuzumab [1]
nd rituximab in combination with chemotherapy
2-4], chronic lymphocytic leukemia (CLL) remains
n incurable disease with standard therapy. Although
utologous transplantation has been attempted as de-
nitive therapy, extended follow-up of high-risk CLL
atients treated with autologous transplantation has
evealed little evidence of a plateau in disease-free
urvival [5-10]. Thus the role and optimal timing of (
056utologous transplantation in the treatment of CLL
emain unclear.
Early studies of myeloablative allogeneic trans-
lantation have established high complete response
ates [11-13], but unfortunately often with signiﬁcant
reatment-related mortality (TRM), ranging from
0% to 40% even in relatively young patients
5,7,12,14-17]. Although relapse rates remain prob-
ematic, ranging from 15% to 40% depending on the
atient population, long-term remissions are possible
15,17-19]. The presence of a graft-versus-leukemia
GVL) effect in CLL is evident in the induction of
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NST for Advanced CLL 1057omplete remissions by donor lymphocyte infusion
DLI) [5,20].
Given this GVL effect, allogeneic stem cell trans-
lantation (SCT) has greater potential than autolo-
ous SCT to overcome poor prognostic features of
he disease. For example, low relapse rates after allo-
eneic SCT have been reported even in CLL patients
ith unmutated immunoglobulin heavy-chain genes
19]. Consequently, interest has turned toward non-
yeloablative allogeneic stem cell transplantation
NST) in an effort to reduce TRM [21-23]. A recent
etrospective comparison of NST patients to matched
atients who received myeloablative conditioning
ound that indeed TRM was reduced in the NST
atients, but this beneﬁt was offset by increased re-
apse rates, leading to equivalent event-free and over-
ll survival [24]. In this article we report the outcome
f all patients with CLL who underwent HLA-
atched NST at Dana-Farber Cancer Institute using
ﬂudarabine and low-dose busulfan conditioning reg-
men. The treatment was well tolerated, with similar
esults in related and unrelated donors, and the pri-
ary predictors of outcome proved to be chemother-
py-responsive disease and degree of bone marrow
nvolvement.
ATIENTS AND METHODS
atient Population
A total of 46 patients with CLL who underwent
LA-matched nonmyeloablative allogeneic stem cell
ransplantation (NST) at Dana-Farber Cancer Insti-
ute between January 2001 and August 2004 were
nalyzed. All patients were treated prospectively on
esearch protocols approved by the Dana-Farber Can-
er Institute Institutional Review Board, and informed
onsent was obtained from all patients before therapy.
ransplantation eligibility requirements included East-
rn Cooperative Oncology Group performance status
–2, left ventricular ejection fraction  30%, and no
ncontrolled infection. The decision to pursue non-
yeloablative rather than myeloablative conditioning
as based on physician and patient preference.
onors
All donors included in this analysis were HLA-
atched at A, B, and DR loci. Unrelated donors were
equired to match recipients by molecular analysis
erformed with sequence-speciﬁc primers. HLA C
ismatches were present in 7 cases. The majority of
atients (98%) received ﬁlgrastim-mobilized periph-
ral blood stem cells (PBSCs). Donors were mobilized
ith ﬁlgrastim at 10 g/kg/day for 5 days. Stem cell
ollection began on day 5 of ﬁlgrastim administration
nd was targeted to collect 6 106 CD34 cells/kg.
or a single patient, bone marrow was collected in the tperating room under anesthesia, and the targeted cell
ose was  2  108 nucleated cells/kg.
onditioning Regimens and GVHD Prophylaxis
All patients were conditioned with ﬂudarabine 30
g/m2/day and intravenous busulfan 0.8 mg/kg/day
n days 6, 5, 4, and 3. All patients received
mmunosuppressive therapy for GVHD prophylaxis
n consecutive GVHD protocols. A total of 43 pa-
ients (93%) received T-cell–replete PBSCs or bone
arrow. Thirteen patients (28%) received GVHD
rophylaxis based on cyclosporine and corticoste-
oids; of these, 8 patients with unrelated donors also
eceived mycophenolate mofetil. Thirty patients
65%) received GVHD prophylaxis based on ta-
rolimus and low-dose methotrexate; of these, 22
lso received sirolimus (73% of the tacrolimus group,
8% of the total). Three patients (6.5%) received
D34-selected PBSCs and cyclosporine for GVHD
rophylaxis. Immunosuppressive medications were ta-
ered as clinically permitted over the 3–12 months
fter NST. All patients received prophylaxis for
neumocystic carinii pneumonia and varicella zoster vi-
us reactivation. Cytomegalovirus infection was ad-
ressed using a preemptive strategy of viral load mon-
toring by hybrid capture. Acute GVHD was graded
ccording to consensus criteria [25].
himerism Analysis
The presence of donor-derived hematopoiesis was
ssessed at various intervals after NST. Donor chi-
erism was assessed on unfractionated bone marrow
spirates and/or peripheral blood at approximately
ay30 (range, day 20–day 50) and day 100 (range,
ay 75–day 120). An additional time point was ob-
ained when possible at 4–7 months posttransplanta-
ion. Genotypes of donor and recipient were deter-
ined using DNA obtained from pretransplantation
amples. Nine short tandem repeat (STR) loci were
yped using the ABI Proﬁler Plus Kit and ABI 310
enetic Analyzer (Applied Biosystems, Foster City,
A). Informative alleles unique to donor or recipient
ere used in the calculations of chimerism.
ytogenetic Analysis and CLL Prognostic Features
Standard metaphase karyotype analysis was per-
ormed on bone marrow aspirates or peripheral blood,
ogether with ﬂuorescence in situ hybridization
FISH) for the most common CLL abnormalities,
ncluding deletion 13q, trisomy 12, deletion 11q, and
eletion 17p. FISH was performed according to stan-
ard clinical protocol using commercial probes for
13S319, CEP12 at 12p11.1-q11.1, ATM at 11q22.3,
nd P53 at 17p13.1 (Vysis, Des Plains, IL). Patients in
hom FISH analysis was not performed and no karyo-
ype abnormalities were identiﬁed were considered
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J. R. Brown et al.1058nevaluable for cytogenetic abnormalities. For analy-
es of the relationship between cytogenetics and out-
ome, patients were classiﬁed as favorable (normal or
el 13q), unfavorable (complex, del 11q, del 17p), or
nevaluable (deﬁned earlier) [26].
Because of the time period in which these patients
ere enrolled, limited data on the mutational status of
he immunoglobulin heavy-chain gene and ZAP-70
re available. The mutational status of the immuno-
lobulin heavy-chain gene was known for 12 patients,
f whom 10 were unmutated ( 98% homology to
ermline). Data on ZAP70 expression was available
or 7 patients, all of whom showed expression  20%.
hese factors were not included in the analysis be-
ause of the incomplete nature of the data.
tatistical Considerations
Descriptive statistical analysis was performed to
valuate patient baseline and transplant characteris-
ics. The 2-sided Fisher’s exact test was used for 2 
table analysis, and the 2-sided Wilcoxon’s rank-sum
est was used for 2-sample comparison of continuous
ariables. Potential predictors for day 30 donor chi-
erism ( 75% vs  75%) and posttransplantation
esponse were examined through logistic regression
nalysis. Complete and partial remission and progres-
ive disease were deﬁned according to the conven-
ional National Cancer Institute Working Group cri-
eria for CLL [27].
Cumulative incidence curves for TRM and relapse
with or without death) were constructed with time to
onrelapse death and time to relapse as competing
isks. Time to relapse and time to nonrelapse death
ere measured from the date of stem cell infusion.
atients who were alive without relapse were censored
t the time last seen alive and free of relapse. Progres-
ion-free survival (PFS) was deﬁned as the time from
tem cell infusion to progression or death from any
ause. Overall survival (OS) was deﬁned as the time
rom stem cell infusion to death from any cause. PFS
nd OS were calculated according to the method of
aplan and Meier. The log-rank test was used for
omparisons of Kaplan-Meier curves. Potential prog-
ostic factors for survival, relapse, and nonrelapse
eath were examined using the proportional hazards
odel and the competing-risks regression model. The
ompeting-risks regression model is a semiparametric
roportional hazards model for subdistribution of re-
apse (or nonrelapse death) in the presence of a com-
eting risk [28].
ESULTS
atient Characteristics
The characteristics of the patient population are
etailed in Table 1. The median patient age was 53 iears, and the median time from diagnosis to NST
as 6.5 years. The patients were heavily pretreated,
ith a median of 5 previous therapies (range, 1–10).
f the 46 patients, 45 (98%) had received ﬂudarabine,
4 (96%) had received alkylating agents, 36 (78%) had
eceived rituximab, and 15 (33%) had received ale-
tuzumab. Ten patients (22%) had relapsed after
revious autologous SCT. Twenty-six patients (57%)
ad progressive chemoresistant disease at the time of
ST, with 50% in active relapse and 7% having failed
o respond to any attempted therapy (induction fail-
re). Only 26% were in partial remission and 17%
ere in complete remission, achieved after a median
f 3 previous therapies. At the time of transplantation,
he median degree of bone marrow involvement was
2.5%, with 18 (39%) patients having  5% involve-
ent and 14 (30%) having  50% involvement. Of
he 35 patients with available cytogenetic information
t any point in their course, 23 had abnormalities, 21
f which were high risk, deﬁned as deletion 11q or 17p
r 2 or more abnormalities (Table 1).
All patients received PBSCs (n  45) or bone
arrow (n  1), along with immunosuppressive med-
able 1. Patient Characteristics
otal number of patients 46
edian age, (range), years 53 (35–67)
ex
Male 34 (74%)
Female 12 (26%)
edian time from diagnosis to NST
(range), years 6.5 (0.2–14.7)
isease status at NST
Induction failures 3 (7%)
Relapse 23 (50%)
PR 12 (26%)
CR 8 (17%)
edian previous therapies (range) 5 (1–10)
Autologous SCT 10 (22%)
Fludarabine 45 (98%)
Alkylators 44 (96%)
Rituximab 36 (78%)
Alemtuzumab 15 (33%)
ytogenetics
Normal 12 (26%)
Del 13q alone 2 (4%)
Abnormal 21 (46%)
Two or more abnormalities 17
Del 17p alone 3
Del 11q alone 1
Not available 11 (24%)
ype of transplant
Matched related donor 15 (33%)
Matched unrelated donor 31 (67%)
VHD prophylaxis
Cyclosporine/prednisone 13 (28%)
Cyclosporine/CD34 selection 3 (7%)
Tacrolimus/methotrexate 8 (17%)
Tacrolimus/methotrexate/sirolimus 22 (48%)cation for GVHD prophylaxis. A total of 67% had a
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NST for Advanced CLL 1059atched unrelated donor (n  31), and 33% had a
atched related donor (n  15). All patients en-
rafted; only 23 (50%) patients developed grade IV
eutropenia, and the median time to neutrophil en-
raftment was 11 days.
VHD and Mortality
The incidence of grade II–IV acute GVHD was
4%, and that of grade III–IV acute GVHD was 19%
Table 2). The incidence of extensive chronic GVHD
as 38%. No difference in the incidence of chronic
VHD was observed between patients with related do-
ors and those with unrelated donors (data not shown).
The day-100 TRM was low (n  1, due to pro-
ressive disease and sepsis), with a 2-year cumulative
RM incidence of 17%. The principal cause of treat-
ent failure was relapse, with a 2-year cumulative
ncidence of 48% (Figure 1). Relapse was also the
rincipal cause of death, responsible for 11 of 18
bserved deaths (Table 3). Other deaths were due
ostly to GVHD and infection. No difference in
elapse (with or without death) or TRM was observed
etween patients with related and unrelated donors
data not shown). A competing-risks regression anal-
sis performed to evaluate factors contributing to
RM found that the primary determinant was refrac-
ory disease at NST (P  .001). All TRM deaths
able 2. Incidence of GVHD
cute grade
0 26 (57%)
1 3 (7%)
2 7 (15%)
3–4 9 (19%)
Unknown 1 (2%)
hronic
None 20 (43%)
Limited 7 (15%)
Extensive 17 (38%)
Unevaluable 2 (4%)*
One death before day 100; one relapse receiving donor lymphocyte
infusion before day 100.
igure 1. Cumulative incidence of TRM and relapse. The 2-year
umulative incidence of TRM is 17%, and that of relapse (with ordithout death) is 48%.ccurred in patients who were not in complete remis-
ion (CR) or partial remission (PR) at the time of
ST.
isease Response after NST
After NST, in the entire patient population, 35%
chieved CR and 24% achieved PR (59% objective
esponses), with 28% with stable disease and 9% with
rogressive disease. Eighteen of 20 patients (90%)
ntering transplantation in objective response main-
ained or improved their objective response after trans-
lantation. Ten of 26 patients (38.5%) entering trans-
lantation in relapse or induction failure achieved an
bjective response.
A univariate logistic regression analysis was per-
ormed to evaluate pretransplantation characteristics
hat might predict objective response after transplan-
ation; factors assessed included age, donor–recipient
ex mismatch, unrelated versus related donor, cytoge-
etics, GVHD prophylaxis regimen, number of pre-
ious therapies, time from diagnosis to NST, degree
f bone marrow involvement, lymphocytosis, and dis-
ase status at NST. Of these, only less bone marrow
nvolvement ( 5%; P  .002) and CR/PR at NST
P .004) proved to be signiﬁcant predictors of ob-
ective response. In multivariate logistic regression
nalysis, signiﬁcant predictors continued to be less
one marrow involvement and CR/PR at NST, along
ith increasing time to NST. Although increasing
ime to NST was a signiﬁcant predictor (P  .04), the
umber of previous therapies was not. DLI was given
o 5 patients with progressive disease, and no objective
esponses were achieved.
FS and OS
In this population of heavily pretreated patients,
he 1-year PFS was 44% and the 2-year PFS was 34%,
ith a median of 10.2 months (95% conﬁdence inter-
al [CI], 5.2–19.1 months) (Figure 2). The 1-year OS
as 66% and the 2-year OS was 54%. Median OS was
ot reached with a median follow-up of 20 months
range, 6–48 months) in surviving patients (Figure 2).
ifteen of 46 patients (32.6%) are presently alive and
isease-free, with a median follow-up of 23.6 months
n this group.
No difference in outcome was observed between
atients with related donors (MRDs) and unrelated
able 3. Causes of Death
elapse 11 (61%)
nfection 2 (11%)
VHD 2 (11%)
nfection  GVHD 2 (11%)
espiratory failure 1 (6%)
otal deaths 18 (100%)onors (URDs). The 2-year PFS for MRD and URD
t
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J. R. Brown et al.1060ransplantations were 36% and 29%, respectively (P
19), and the corresponding 2-year OS were 46% and
3%, respectively (P  .50). Neither acute nor
hronic GVHD was predictive of PFS or OS (data not
hown).
Disease status at NST predicted both PFS and
S. For those patients in CR/PR at NST, the 2-year
FS was 60% and the OS was 84%, compared with PFS
f 15% (P .008) and OS 34% (P .01) for those with
rogressive disease or induction failure (Figure 3). Bone
arrow involvement was signiﬁcant only in predicting
FS; 5% bone marrow involvement before trans-
lantation was associated with a 2-year PFS of 8%
P  .0008; Figure 4). Cytogenetics was also signiﬁ-
ant in predicting only PFS, with a 2-year PFS of 53%
or those patients with favorable cytogenetics (normal
r del 13q), compared with 11% for those with ad-
erse cytogenetics (complex, or del 17p or 11q) (P 
02). The corresponding 2-year OS values were 75%
nd 30%, respectively (P  .08).
A competing-risks regression analysis was per-
ormed to assess for factors contributing to relapse or
eath due to relapse. The primary factors identiﬁed
ere bone marrow involvement  5% (P  .03),
ncreasing lymphocyte count (P  .02), and abnormal
ytogenetics (P  .03). Of the 10 patients who had
ndergone previous autologous SCT (only 1 of whom
as in objective response at time of NST), 3 are alive
nd free of disease, whereas 4 have died of disease and
of TRM. Previous treatment with alemtuzumab had
o impact on TRM or overall outcome.
A multivariate Cox proportional hazards model
as constructed to evaluate the impact of pretrans-
lantation parameters on PFS and OS. Factors found
o be not signiﬁcant but nonetheless adjusted for in
he analysis include age, sex mismatch, and GVHD
rophylactic regimen. Signiﬁcant predictors of both
igure 2. Probability of PFS and OS. The 1-year PFS is 44% and
he 2-year PFS is 34%, with a median PFS of 10.2 months (95% CI
.2–19.1 months). The 1-year OS is 66% and the 2-year OS is 54%,
ith median OS not yet reached at a median follow-up of 20
onths.FS and OS included disease status at baseline, num- ier of previous therapies, and degree of bone marrow
nvolvement with CLL (Table 4). Not surprisingly,
he number of previous therapies was inversely corre-
ated with disease status (P  .02). Bone marrow
nvolvement measured as a continuous variable was
redictive of both PFS (P  .01) and OS (P  .0007);
one marrow involvement  5% was associated with
n 8-fold increased risk of disease progression (P 
igure 3. Disease status at NST predicts PFS and OS. (A) Two-
ear PFS for those in CR/PR at NST is 60%, compared with 15%
or those in relapse or induction failure (P  .008). (B) Two-year
S for those in CR/PR at NST is 84%, compared with 34% for
hose in relapse or induction failure (P  .01).
igure 4. Bone marrow involvement with CLL predicts PFS. Two-
ear PFS for patients with5% bone marrow replacement by CLL
s 8%, compared with 63% for all others (P  .0008).
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NST for Advanced CLL 10610002) but was not signiﬁcant in predicting OS
P  .06). Increasing lymphocytosis was also inde-
endently predictive of worse PFS (P  .03). Al-
hough disease status at NST, number of previous
herapies, bone marrow involvement, and lymphocy-
osis were independent predictors of outcome, they
ere signiﬁcantly correlated; of these, disease status at
ST and bone marrow involvement proved the stron-
est predictors of PFS and OS. Adverse cytogenetics
as not a signiﬁcant predictor of either PFS or OS in
ultivariate analysis.
ematopoietic Donor Chimerism and Outcome
Of the 43 patients who could be evaluated for
ematopoietic donor chimerism at day30, 24 (56%)
ad both bone marrow and peripheral blood assess-
ents, 15 (35%) had only bone marrow assessment,
nd 4 (9%) had only peripheral blood assessment. In
hose who had both bone marrow and peripheral
lood chimerism, the results were highly correlated
correlation coefﬁcient 0.85; P  .0001); thus, these
esults were considered together in the analysis. Re-
idual bone marrow disease is unlikely to have inﬂu-
nced the chimerism analysis, because only 3 of the 15
atients with bone marrow chimerism alone had 
5%CLL in their bone marrow. Furthermore, at least
subjects with 50% bone marrow involvement with
LL had  75% bone marrow chimerism in this
ssay.
Overall, the median donor chimerism achieved on
ay 30 was 87% (range, 0–100%). Twenty-ﬁve of
3 patients (58%) achieved  75% donor chimerism
y day30, and 88% maintained this at day100 (15
f 17 patients) and at 6 months (13 of 15 patients).
mong the 13 patients with  75% donor chimerism
t day 30, only 2 (15%) developed  75% chimer-
sm at day 100.
The impact of high early donor chimerism on
ubsequent disease control was assessed. Donor chi-
erism equal to or greater than 75% at day 30
as associated with a 28% risk of relapse or death
able 4. Multivariate Cox Proportional Hazards Model, PFS and OS
PFS OS
Hazard
Ratio P
Hazard
Ratio P
isease status (no CR/PR) 3.18 .01 4.56 .02
umber previous therapies 1.39 .002 1.32 .02
ime to NST 0.99 .91 0.99 .85
dverse cytogenetics 2.33 .10 2.63 .15
one marrow > 5% CLL 8.0 .0002 2.96 .06
one marrow involvement
(continuous variable) 1.02 .01 1.03 .0007
ymphocyte count
(continuous variable) 1.29 .03 1.04 .80rom disease, compared with a 72% risk for thoseith  75% donor chimerism at day 30 (P 
006). Two-year PFS for those with chimerism 
5% was 47%, compared with 11% for those with
himerism  75% (P  .03; Figure 5). Donor chi-
erism was not signiﬁcant in predicting OS (P 
95). In multivariate Cox regression analysis, chi-
erism remained a signiﬁcant predictor of PFS but
ot of OS.
Given the association between chimerism and
FS, pretransplantation factors were evaluated to
etermine whether they were predictive of donor
himerism  75% at day 30. In multivariate lo-
istic regression analysis adjusting for age, sex mis-
atch, unrelated versus related donor, and GVHD
rophylaxis regimen, signiﬁcant predictors of 
5% chimerism included CR/PR at NST, less bone
arrow involvement with CLL, and lower lympho-
yte count (Table 5). Patients in objective response
t time of transplantation were 6.7 times more likely
o achieve  75% donor chimerism (P  .04), and
atients with  5% bone marrow involvement were
0.8 times more likely to achieve  75% chimerism
P  .01). Time from diagnosis to NST, number of
revious therapies, and cytogenetics were not sta-
istically signiﬁcant predictors of donor chimerism.
igure 5. High early donor chimerism predicts PFS. Hematopoi-
tic donor chimerism  75% at day 30 is associated with a 2-year
FS of 47%, compared with 11% for those with lesser chimerism
P  .03).
able 5. Factors Predictive of High Early Donor Chimerism
Odds Ratio P
one marrow involvement < 5% 10.8 .01
ncreasing bone marrow involvement
(continuous variable) 0.97 .03
ymphocyte count 0.29 .005
R/PR at NST 6.7 .04
ge, sex mismatch, URD versus MRD, cytogenetics, GVHD pro-
phylaxis regimen, number of previous treatments, and time to
NST are not signiﬁcant at the .05 level.
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J. R. Brown et al.1062ISCUSSION
The timing and role of SCT in the treatment of
hronic lymphocytic leukemia remain controversial.
e report a nonmyeloablative SCT approach using
ow-dose intravenous busulfan and ﬂudarabine, which
s well tolerated in a heavily pretreated population of
LL patients and associated with a 54% 2-year OS in
ll patients. Even heavily pretreated patients with che-
osensitive disease achieved a 60% 2-year PFS. The
rimary predictors of outcome proved to be disease
tatus at transplantation and bone marrow involve-
ent with CLL. High early donor chimerism was
ssociated with improved PFS.
The safety of this transplantation approach is no-
able, particularly given that 2/3 of this heavily pre-
reated, older patient population had an unrelated
onor. Only 1 death occurred within 100 days, and
his death was not related to the conditioning regi-
en. Those patients with therapy-responsive disease
ho came to transplantation in objective response had
o TRM. These results are comparable with our
ecently reported experience with autologous and
-cell–depleted sibling-matched ablative allogeneic
ransplantations, in which the 100-day mortality was
% and the subsequent mortality was 17%–24% [5].
Our observed 2-year OS of 54% is comparable
ith that in other recently reported series of NST in
LL [21,23], despite a patient population that was
niversally pretreated with ﬂudarabine and alkylating
gents, with a median of 5 previous regimens and 6.5
ears between diagnosis and transplantation. This pa-
ient population historically has a median survival of
2–18 months [1]. Disease status at transplantation
roved to be a very strong predictor of both PFS and
S. Given that more than half of the patients had
ctively progressive disease at transplantation, and
onsidering the low-dose conditioning regimen, it is
ot surprising that disease status should prove an im-
ortant predictor of outcome. A high number of
revious therapies was similarly related to outcome,
lthough it was also correlated with disease status.
ther studies of NST in less heavily pretreated pa-
ients have also found that a greater number of previ-
us therapies [22] and chemotherapy-refractory dis-
ase [15,23,29] were associated with worse outcome.
ot surprisingly, the degree of bone marrow disease
as also a very signiﬁcant independent predictor of
FS and was also signiﬁcant for OS. The Seattle
roup has also identiﬁed bone marrow involvement
nd bulky lymphadenopathy as predictors of poor
rognosis in CLL patients undergoing NST [21].
hether bone marrow cytoreduction before trans-
lantation, perhaps with agents like alemtuzumab that
re particularly effective in clearing bone marrow dis-
ase, would improve outcome remains an unanswered
uestion for future study. mThe impact of adverse cytogenetics on transplan-
ation outcome is only beginning to be explored. In
his study, adverse cytogenetic features were associ-
ted with reduced PFS in univariate analysis but not in
ultivariate analysis. Even though this cytogenetic
nalysis and all other studies to date were limited by
mall patient numbers and incomplete data, selected
atients with deletions of 11q or 17p have responded
o NST [21,22]. Although these observations remain
reliminary, they suggest that, at least in some cases,
ST may be able to overcome adverse cytogenetic
eatures in CLL. Whether NST can truly and system-
tically overcome the poor prognosis associated with
dverse cytogenetics remains to be established in fu-
ure clinical trials.
Further research is also needed to elucidate the
echanisms of treatment failure after NST. Whether
hemotherapy-refractory disease predicts intrinsic re-
istance to graft-versus-CLL activity is unclear; alter-
atively, it could be a marker of aggressive disease that
rogresses too rapidly to be controlled by even an
ctive immune response. The relatively low rate of CR
fter NST in this study and the infrequent use and
oor success of DLI reﬂect the rapid disease progres-
ion in many of these chemotherapy-refractory pa-
ients. The possible impact of different GVHD pro-
hylaxis regimens on objective response rates and
himerism is unknown but was not signiﬁcant in the
tatistical analysis. Furthermore, the fact that 38% of
ur heavily pretreated patients with refractory disease
chieved an objective response and 33% of the entire
opulation is alive and disease-free at present suggests
ome capacity of graft-versus-CLL reaction to control
he disease, at least transiently. The association of
igh early donor chimerism with PFS further supports
his suggestion, although it remains unclear whether
chieving high early donor chimerism is primarily a
unction of disease status before transplantation or of
raft-versus-CLL activity. Regardless, research efforts
o enhance early donor chimerism and GVL could
nclude better cytoreduction with bone marrow de-
ulking before NST, early tapering of immunosup-
ression, early planned DLI, or vaccination strategies.
Our study conﬁrms promising OS for heavily pre-
reated patients with CLL undergoing NST with ﬂu-
arabine and low-dose intravenous busulfan. Not sur-
risingly, however, disease outcomes were determined
rimarily by disease characteristics; the patients with
hemotherapy-sensitive disease did reasonably well,
ven when heavily pretreated, whereas those with pro-
ressive chemotherapy-refractory disease or extensive
one marrow involvement were poor candidates for
ST unless their disease responded to additional
fforts at cytoreduction before NST. Even so, GVL
ffects alone are unlikely to be adequate for long-term
isease control in most advanced patients with che-
otherapy-refractory disease. The results of this
s
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NST for Advanced CLL 1063tudy, in which patients undergoing NST in objective
esponse had no TRM and had signiﬁcantly better
urvival, support the potential safety and efﬁcacy of
erforming NST earlier in the disease course for
LL. Future studies should focus on early NST for
igh-risk patients, as well as approaches to optimize
nd maintain donor chimerism and GVL over time.
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